Previous reviews have described in detail the studies in our laboratory from which evidence has been accumulated that there are at least five different mutants causing hyperlipoproteinemia2' 3 and one leading to high-density lipoprotein (HDL) deficiency (Tangier disease).4 When these are added to mutants causing absence or decrease in low-density lipoprotein (LDL),5. 6 the number of abnormal genotypes that are now recognizable and expressed primarily by an alteration in lipoprotein concentrations is not less than ten (Table 1) .
Recent research on the structure of lipoproteins has kindled new interest in some of these mutants. I have particular reference to the expansion of the number of known polypeptide chains (apolipoproteins) in the lipoproteins from two to five. As identified by their COOH-terminal residues, an apoHDL-Gln has been added by the work of Shore and Shore to the apoHDL-Thr previously considered the only apolipoprotein in high density lipoproteins.10 Brown et al. have recently described an apoVLDL-Ala and apoVLDL-Val" in the polypeptides associated with very-low-density lipoproteins (VLDL). Thus far, the polypeptides in low-density lipoproteins consist mainly of an apoLDI-Ser which also is a significant contributor to apoVLDL. In Figure 1 , these apolipoproteins are designated R-Thr, etc.
Magnitude of Fat Transport in Lipoproteins.-The magnitude of fat transported by the several classes of lipoproteins is summarized in Table 2 . The estimates are of net transport; the major tasks involve movement of fatty acids, and the amounts transported during a given period often considerably exceed the amount oxidized. The largest single contributor to fatty acid transport is the free fatty acid-albumin complex. This is not a lipoprotein but free fatty acid flux exerts an effect on lipoprotein concentrations. This is particularly true of the VLDL, one of whose functions is to return free fatty acid released in excess of caloric demand back to the adipose tissue in the form of triglycerides.'3 Transport in chylomicrons is regulated by dietary intake, since it is in this form that ingested fats reach the tissues through the blood. Only a fraction of these glyc-1138 HDL and quantities of the abnormal "HDIT" similar to those in homozygotes.'9 It will now be possible to determine if the mutation selectively affects apoHDLThr or apoHDL-Gln. Tangier disease has thus far not revealed the functions of apoHDL but has indicated that apoHDL does not appear necessary for VLDL and chylomicron formation. The homozygote accumulates cholesteryl esters in many tissues of the body, but the manner in which HDL maintain cholesterol equilibrium between tissue and plasma is not known. One possibility is a role of HDL in plasma lecithin: cholesterol acyltransferase activity;20 a genetically determined deficiency of this enzyme is associated with low HDL concentrations.2' It has been reported that a small amount of a COOH-terminal apolipoprotein is present in the HDL density region,22 and LaRosa in our laboratory has discovered that antigens identical to apoVLDL-Ala and apoVLDL-Val are present in HDL and that their amounts increase upon activation of lipolytic activity in plasma.23 Tangier disease thus also offers an opportunity to explore suggested relationships between apoVLDL and apoHDL.
Type III hyperlipoproteinemia: Of mutations leading to excessive concentrations of certain lipoproteins, one is suspected but not proved to be due to a change in the structure of an apoprotein. This is the disorder first described as "xanthoma tuberosum"24 and proved to be a genetic variant in the NIH studies in which it is called type III hyperlipoproteinemia.2 In Miendelian terms the mutant behaves as an autosomal recessive with incomplete penetrance. The characteristic lipoprotein anomaly (Fig. 3) is due to the presence in VLDL of an ab- The frequency of the type II gene(s) in the general population is unknown; it is probably greater than 1: 10,000 and could be as high as 1: 1,000. The life span of heterozygotes may be reduced by a tendency to accelerated atherosclerosis. Homozygotes often do not live to the child-bearing age.
The metabolic error in type II is unknown. In heterozygotes, LDL concentrations can be lowered by restricting cholesterol intake and increasing the polyunsaturated fatty acids in the diet, and administering drugs that increase excretion of bile acids. Once therapy is suspended, the LDL pool expands again to its abnormal level. Recent measurements of the disappearance of LDL tagged in the apoprotein have indicated that the fractional turnover rate of LDL in type II is decreased.32 It is not possible to deduce whether this is due to a rate limitation in the catabolism of a component of LDL or the lipoprotein as a whole.
Demand for Fat Transport.-The most important determinant of acute and chronic changes in lipoprotein concentrations is the demand for fatty acid transport. Carbohydrates spare the utilization of fatty acids in most tissues. The glyceryl-PO4 derived from carbohydrate breakdown is also essential for facilitating the re-esterification in adipose tissue necessary for disposal of chylomicron and VLDL triglycerides. Insulin is almost the sole force opposing many lipolytic factors that act to increase FFA flux from adipose tissue. 3 Insulin deficiency also decreases the lipolytic activity required for glyceride removal.34 Thus, a mutant or mutants affecting insulin activity may also be determinants of various lipoprotein abnormalities.
Caloric supply also regulates lipoprotein levels. An acute excess, far exceeding that demanded for energy balance, elevates lipoprotein concentrations in normal men." Negative caloric balance promptly causes abnormal concentrations of VLDL to fall.
Triglyceride concentrations are also rapidly responsive to the metabolic mixture consumed. This is illustrated in Figure 4 in a simple experiment involving normal young adults fed three different diets for each of three 7-day periods. Triglyceride concentrations on the last day of each diet are plotted in relation to the three meals. A diet containing mainly fat and almost no carbohydrate (II, Fig. 4 ) halves the fasting glyceride (VLDL) concentrations and induces wide oscillations in glycerides (chylomicrons) following each meal. Reversal of the content of fat and carbohydrate (III, Fig. 4 There is evidence of several mutants in the American population that have defective responses to fat transport demand. These fall into the type IV and type V summarized in Table 1 and illustrated in Figure 5 . Evidence for their segregation has been given elsewhere.2 3 Type IV behaves as though it were a single autosomal mutant, about 50 per cent of first-degree adult relatives of propositi being similarly affected. The involvement of relatives in type V is more extensive. Children are rarely affected; more than half of the patients have VOL. 64, 1969 eride removal. The common mutation(s) giving rise to the hyperbetalipoproteinemia that is characteristic of type II hyperlipoproteinemia probably causes a rate-limiting defect in the catabolism of either cholesterol or LDL. Finally, there are other diseases leading to hyperlipoproteinemia, grouped as type IV or type V hyperlipoproteinemia, that seem clearly due to mutations but the defects are obscure. Most likely they are related to adjustments required by changing demands for fat transport. The paramount importance of insulin activity threads through several of these disorders and it is obvious that the gene or genes for diabetes cannot now be clearly separated from some of those causing the latter forms of hyperlipoproteinemia. Recently acquired new knowledge of the structure of lipoproteins can be expected to assist in study of the regulation of fat transport in lipoproteins and mutations affecting these processes. Most notable is the recent discovery of three new polypeptides among the apoproteins: apo-HDL-Gln, apoVLDL-Ala, and apoVLDL-Val, all of whose functions and interrelationships with each other and the more established apolipoproteins remain to be determined.
